Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
:KYTX
RESEARCH TOOLSreports
Total Valuation
Kyverna Therapeutics, Inc. has a market cap or net worth of $87.30M. The enterprise value is -$116.11M.
Market Cap$87.30M
Enterprise Value-$116.11M
Share Statistics
Kyverna Therapeutics, Inc. has 43,218,872 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,218,872
Owned by Insiders0.18%
Owned by Institutions11.34%
Financial Efficiency
Kyverna Therapeutics, Inc.’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -51.89%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-51.89%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.14M
Employee Count112
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kyverna Therapeutics, Inc. is -1.12. Kyverna Therapeutics, Inc.’s PEG ratio is >-0.01.
PE Ratio-1.12
PS Ratio0.00
PB Ratio0.54
Price to Fair Value0.54
Price to FCF-1.23
Price to Operating Cash Flow-1.25
PEG Ratio>-0.01
Income Statement
In the last 12 months, Kyverna Therapeutics, Inc. had revenue of 0.00 and earned -127.48M in profits. Earnings per share was -3.33.
Revenue0.00
Gross Profit0.00
Operating Income-142.60M
Pretax Income-127.48M
Net Income-127.48M
EBITDA-142.60M
Earnings Per Share (EPS)-3.33
Cash Flow
In the last 12 months, operating cash flow was -95.75M and capital expenditures -2.01M, giving a free cash flow of -97.76M billion.
Operating Cash Flow-95.75M
Free Cash Flow-97.76M
Free Cash Flow per Share-2.26
Dividends & Yields
Kyverna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.47
52-Week Price Change-85.41%
50-Day Moving Average2.24
200-Day Moving Average4.48
Relative Strength Index (RSI)49.61
Average Volume (3m)258.24K
Important Dates
Kyverna Therapeutics, Inc. upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Kyverna Therapeutics, Inc. as a current ratio of 8.61, with Debt / Equity ratio of 3.02%
Current Ratio8.61
Quick Ratio8.61
Debt to Market Cap0.06
Net Debt to EBITDA0.62
Interest Coverage Ratio1.00K
Taxes
In the past 12 months, Kyverna Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kyverna Therapeutics, Inc. EV to EBITDA ratio is -0.39, with an EV/FCF ratio of -0.47.
EV to Sales0.00
EV to EBITDA-0.39
EV to Free Cash Flow-0.47
EV to Operating Cash Flow-0.48
Balance Sheet
Kyverna Therapeutics, Inc. has $321.59M in cash and marketable securities with $10.56M in debt, giving a net cash position of -$312.45M billion.
Cash & Marketable Securities$321.59M
Total Debt$10.56M
Net Cash-$312.45M
Net Cash Per Share-$7.23
Tangible Book Value Per Share$6.95
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kyverna Therapeutics, Inc. is $15.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.25
Price Target Upside654.95% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―